Exercise price determined for the exercise of warrants of series TO 6 in Alligator Bioscience AB
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series TO 6 (the “warran ...
Alligator Bioscience announce milestone achievement in 2021 Immuno-Oncology Research Collaboration and License Agreement with Orion Corporation
Technical Feasibility achieved in second collaboration project triggering new milestone payment to Alligator Collaboration aims to discover ...
Alligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business update
Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...
Alligator Bioscience to Present its CD40 Program at the 3rd Annual Tumor Myeloid-Directed Therapies Summit in July 2023
Presentation highlights very promising interim efficacy analysis from mitazalimab OPTIMIZE-1 Phase 2 study in pancreatic cancer Latest analy ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Alligator Bioscience AB (publ) today announces that Anette Sundstedt, PhD, Principal Scientist at Alligator, has been appointed as employee ...
Phase 2 results indicate durability of response for Alligator’s CD40 agonist
BioStock interview with Alligator CMO, Sumeet Ambarkhane. Following the second round of interim results from OPTIMIZE-1, the phase 2 trial w ...
Change in number of shares and votes in Alligator Bioscience AB
During June 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of the ...
Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...
Alligator Bioscience to Host Virtual Key Opinion Leader Event on Mitazalimab Latest Interim Phase 2 Data in 1st Line Metastatic Pancreatic Cancer
June 27, 2023 – 9:00 AM ET / 3:00 PM CET Featuring Dr. Zev Wainberg from UCLA Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) ...